Astellas Pharma Faces Currency Losses in FY2024
Company Announcements

Astellas Pharma Faces Currency Losses in FY2024

Astellas Pharma (JP:4503) has released an update.

Astellas Pharma Inc. reported a foreign exchange loss of ¥12.2 billion for the first half of FY2024, following fluctuations in currency rates that led to a significant loss in the second quarter despite gains in the first quarter. These financial results highlight the impact of currency valuations on the company’s monetary assets and liabilities.

For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.

Related Articles
Austin AngeloALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
TipRanks Japan Auto-Generated NewsdeskAstellas Pharma Withdraws EU Application for Key Drug
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App